Gene editing allows precise changes in DNA.
CRISPR technology has made this process faster and cheaper.
As a result, ethical concerns have grown rapidly.
One major issue is human germline editing.
Changes made to embryos can pass to future generations.
This raises questions about consent and long-term risk.
Safety remains a central concern.
Off-target mutations may occur.
These unintended changes can cause serious harm.
Equity is another ethical challenge.
Advanced gene therapies are expensive.
Access may be limited to wealthy populations.
There is also fear of genetic enhancement.
Editing for intelligence or physical traits is controversial.
It may lead to social inequality.
Regulatory oversight differs across countries.
Some nations allow limited research on embryos.
Others impose strict bans on germline editing.
International guidelines exist but lack enforcement.
This creates gaps in global governance.
Researchers may seek permissive regions.
Clinical applications face strict approval processes.
Regulators demand strong evidence of safety and benefit.
Patient protection remains the priority.
Public engagement is essential.
Societal values must guide scientific progress.
Transparency builds trust in gene editing research.
Ethical frameworks continue to evolve.
Regulations are adapting with new discoveries.
Responsible innovation will shape the future of gene editing.
CMP Bio World 